The VJSessions have brought together leading experts virtually to help continue the valuable international collaborations in diseases such as Multiple Myeloma, CLL, AML, Lymphoma, MDS and MPNs. You can view our collection of webinar sessions below at your convenience, as well as being able to listen to podcasts of each session on the go.
Multiple Myeloma
26 Apr 2026
T-cell engagers & CARs for myeloma: trispecifics, anito-cel updates, & long-term CARTITUDE-4 data
12 Apr 2026
Immunotherapies in myeloma: novel bispecific data, off-the-shelf CAR-T, and trispecific approaches
12 Apr 2026
Early use of immunotherapy in myeloma: TecDara, bispecific consolidation, and alpha emitter therapy
11 Apr 2026
Integration of clinical and translational research in myeloma: ongoing work of the MMRF
11 Apr 2026
Advances in myeloma genomics: characterizing structural variation and identifying prognostic factors
11 Apr 2026
Novel approaches to targeting resistance mechanisms in multiple myeloma
11 Apr 2026
Expanding our understanding of the role of the tumor microenvironment in multiple myeloma
13 Mar 2026
Treatment considerations with GPRC5D-targeted therapies in myeloma: optimizing sequencing
12 Mar 2026
GPRC5D-directed therapies in myeloma: mechanisms of resistance & strategies to overcome resistance
12 Mar 2026
Latest real-world & clinical evidence with GPRC5D therapies: toxicity, safety & QoL
24 Oct 2025
Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting
24 Oct 2025
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
23 Oct 2025
Immuno- and targeted therapies in high-risk myeloma: ADCs, targeting GPRC5D & more
23 Oct 2025
Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level
13 Apr 2025
Important considerations for community oncologists regarding the use of T-cell therapies in myeloma
13 Apr 2025
Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics
12 Apr 2025
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more
12 Apr 2025
Genomics & epigenomics in multiple myeloma: key updates and potential clinical applications
12 Apr 2025
Evaluating mechanisms of resistance to myeloma therapies & implications for clinical practice
12 Apr 2025
Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more
12 Apr 2025
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
11 Apr 2025
MRD as an early endpoint for accelerated approval in myeloma: current perspectives & future outlooks
11 Apr 2025
Clinician & patient perspectives on the value of MRD in myeloma: what should patients know?
11 Apr 2025
Ongoing research at the MMRF: Horizon Clinical Trials Program
11 Apr 2025
Novel technologies being explored for MRD detection in myeloma: CTCs, NGS & more
22 Mar 2025
iwGPRC5D 2025: highlights from the workshop
04 Nov 2024
CTCs in HRMM: their value in diagnosis, prognosis, and guiding treatment decisions
04 Nov 2024
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
04 Nov 2024
CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs
04 Nov 2024
Defining high-risk multiple myeloma: recent advances in the field & future considerations
04 Nov 2024
Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more
04 Nov 2024
An insight into designing randomized studies in high-risk myeloma
26 Sep 2024
Immune profiling of BM microenvironment to identify predictors of disease progression in myeloma
26 Sep 2024
Analyzing the BM immune microenvironment in RAS/RAF-mutated myeloma treated with a MEK inhibitor
03 May 2024
The value of genomics in multiple myeloma & applying this in clinical practice
03 May 2024
Understanding mechanisms of resistance to targeted therapies in myeloma
03 May 2024
Improving our understanding of myeloma biology: mouse models, epigenetics & spatial transcriptomics
03 May 2024
Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more
03 May 2024
Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities
03 May 2024
Novel targets & agents in myeloma
03 May 2024
History and upcoming projects of the MMRF
25 Mar 2024
SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
25 Mar 2024
Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
25 Mar 2024
Early interception in SMM & novel agents being explored
14 Mar 2024
Roundtable Discussions from IBC 2024
27 Sep 2023
Session highlights and overview: exploring the cellular origins of multiple myeloma
24 Jun 2023
Key myeloma highlights from EHA 2023
09 Jun 2023
Key highlights from EHA 2023
12 May 2023
Updates in multiple myeloma
15 Apr 2023
Updates in the genomics of SMM & multiple myeloma
15 Apr 2023
Resistance mechanisms mediated by the microenvironment in multiple myeloma
15 Apr 2023
Using animal models & the microenvironment to better understand the biology of multiple myeloma
15 Apr 2023
The future of myeloma therapy
15 Apr 2023
Novel therapeutic strategies in multiple myeloma
15 Apr 2023
Reaching a cure for multiple myeloma
17 Mar 2023
iwMyeloma 2023
11 Dec 2022
Identification of a T-cell population associated with outcomes in myeloma with t(4;14) translocation
10 Dec 2022
Key highlights from ASH 2022
10 Dec 2022
Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks
15 Sep 2022
Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
15 Sep 2022
Management of high-risk and frail patients, MRD & teclistamab
15 Sep 2022
Optimal management of intermediate-fit and frail elderly patients with myeloma & refining frailty
15 Sep 2022
The role of super-enhancers in multiple myeloma & mechanisms of resistance to IMiDs and T cell-directed therapies
27 Aug 2022
Updates from IMS 2022
15 Jul 2022
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
14 Jun 2022
Myeloma treatment updates: a UK perspective
11 Jun 2022
Myeloma updates from EHA 2022
12 May 2022
Myeloma treatment in the UK
01 May 2022
Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma
30 Apr 2022
iwCAR-T 2022 day 3 highlights with a focus on myeloma
27 Mar 2022
PIKfyve, RAS, the epigenome & PROTAC therapy
27 Mar 2022
Day 2 wrap-up: pushing myeloma boundaries
27 Mar 2022
T-Cell Engagers: targets, challenges and opportunity
27 Mar 2022
Novel Targets: PIKfyve, RAS, the epigenome & PROTAC therapy
26 Mar 2022
Day 1 highlights from Myeloma 2022
26 Mar 2022
Day 2 highlights from Myeloma 2022
26 Mar 2022
T-Cell engagers
26 Mar 2022
Novel targets in 2022
26 Mar 2022
Using single-cell analysis to tackle myeloma
26 Mar 2022
Genomics in the age of I-O
26 Mar 2022
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
26 Mar 2022
Novel targets in 2022
26 Mar 2022
Genomics in the age of I-O
26 Mar 2022
Using single-cell analysis to tackle myeloma
27 Jan 2022
Post-ASH 2021
11 Dec 2021
A deep dive into screening for precursor conditions
11 Dec 2021
Screening for myeloma precursors: iStopMM, PROMISE, and the questions they have raised
11 Sep 2021
Next steps for myeloma research and treatment
11 Sep 2021
Patient segmentation for targeted therapy in myeloma
10 Sep 2021
Women in myeloma
10 Sep 2021
The new era of myeloma therapies
10 Sep 2021
Screening programs for plasma cell disorders
10 Sep 2021
Precursor conditions: management of smoldering myeloma
09 Sep 2021
Patient empowerment in myeloma
09 Sep 2021
IMW 2021 award winners
09 Sep 2021
MRD in myeloma: the FDA perspective
09 Sep 2021
Long-term disease-free survival in myeloma
09 Sep 2021
Key highlights of IMW 2021
09 Sep 2021
The IMW 2021 congress and COVID-19
20 Jul 2021
Post-EHA/ASCO 2021
08 Jun 2021
The patient perspective
20 May 2021
Post-COMy 2021
13 Jan 2021
Post-ASH 2020
13 Jan 2021
Post-ASH 2020 UK
13 Aug 2020
Myeloma & COVID-19
01 Jul 2020
COMy & EHA 2020
11 Oct 2019
CAR T-cell therapy in myeloma
11 Oct 2019
Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
25 Sep 2019
Highlights from IMW 2019 Part I
14 Sep 2019
An MRD discussion: when, who and how
14 Sep 2019
Advances in the clinical management of SM
14 Sep 2019
PROMISE: why early detection of MGUS is vital to reducing MM incidence
14 Sep 2019
How will novel agents affect the amyloidosis population?
14 Sep 2019
The evolving myeloma diagnosis criteria
14 Sep 2019
MRD as a surrogate endpoint: what remains for FDA approval?
14 Sep 2019
Translating myeloma genomics into treatment strategies
14 Sep 2019
MRD evaluation: a key component of MM management?
13 Sep 2019
CAR-T: hurdles and ladders
13 Sep 2019
Transplantation in modern myeloma therapeutics
13 Sep 2019
Does maintenance therapy increase overall survival in myeloma?
13 Sep 2019
Targeted therapy in MM
12 Sep 2019
Immunotherapy in myeloma: current strategies and future perspectives
02 Dec 2018
The definitive guide to multiple myeloma at ASH 2018: part I
02 Dec 2018
The definitive guide to multiple myeloma at ASH 2018: part II
02 Dec 2018
The definitive guide to multiple myeloma at ASH 2018: part III
02 Dec 2018
The definitive guide to multiple myeloma at ASH 2018: part IV
02 Dec 2018
The definitive guide to multiple myeloma at ASH 2018: part V
10 Sep 2018
Is MRD testing ready for prime time in myeloma?
10 Sep 2018
MRD detection in myeloma: single cell RNAseq, protein-based & VDJ sequencing
09 Sep 2018
Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
09 Sep 2018
The role of the microenvironment in multiple myeloma
09 Sep 2018
How can novel targets be incorporated into MM treatment?
09 Sep 2018
Genomics and proteomics of drug resistance in myeloma: PIs, IMiDs & CD38
07 Sep 2018
Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance
07 Sep 2018
Myeloma 2018 day 1 highlights: precision medicine, epigenetics & novel targets
07 Sep 2018
CAR T-cells in myeloma: exploratory targets & payment models
07 Sep 2018
Where in the treatment sequence should CAR T-cells be used for myeloma?
07 Sep 2018
Progression and treatment of MGUS-SMM-MM & epigenetics
07 Sep 2018
Is precision medicine a bust in myeloma?
18 Oct 2017
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
18 Oct 2017
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
18 Oct 2017
Debate on the use of MRD for multiple myeloma management
18 Oct 2017
Optimism for the use of liquid biopsies in multiple myeloma
18 Oct 2017
Re-evaluating the role of epigenetics in multiple myeloma
18 Oct 2017
Multiple myeloma: consensuses and controversies
18 Oct 2017
Multiple myeloma: genomic evolution
18 Oct 2017
The exciting field of imaging in multiple myeloma
18 Oct 2017
The use of CAR T-cells in multiple myeloma
18 Oct 2017
Novel therapeutics in multiple myeloma
18 Oct 2017
The future of immunotherapy in multiple myeloma
18 Oct 2017
Why use model systems for multiple myeloma research?
18 Oct 2017
Exciting new developments in multiple myeloma
22 Apr 2017
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
21 Apr 2017
COMy 2017: Day 1 discussion on progress in multiple myeloma, patient advocacy and drug costs
20 Feb 2017
Triple combination therapies for multiple myeloma (MM) patients
27 Jan 2017
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
27 Jan 2017
Working towards a cure for multiple myeloma
16 Sep 2016
New tools for multiple myeloma treatment monitoring
16 Sep 2016
Frontline treatment for young multiple myeloma patients
16 Sep 2016
An update on immunotherapy for multiple myeloma in 2016
16 Sep 2016
Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory
16 Sep 2016
Are we ready for mutational directed treatment: addressing the genomic basis of myeloma
14 Jun 2016
Myeloma 2016: Panel discussion on in vivo drug screening
14 Jun 2016
Myeloma 2016: Panel discussion on the status of genomics
14 Jun 2016
Myeloma 2016: Panel discussion on the application of genomics studies
05 May 2016
Myeloma 2016: Panel discussion on the new treatment paradigm
29 Apr 2016
COMy 2016: Highlights from Day 1
28 Apr 2016
A multiple myeloma patient story - a discussion between Vivien de Gunzburg and Paul Richardson
28 Apr 2016
How to address the issue of access to new drugs in multiple myeloma
28 Apr 2016
Highlights from COMy and how to reset the immune system in multiple myeloma
28 Apr 2016
The importance of multiple myeloma foundations and a patient story
23 Apr 2016
COMy 2016: Highlights from Day 2
22 Apr 2016
Myeloma 2016: Panel discussion on the environment biology of myeloma
22 Apr 2016
Myeloma 2016: Panel discussion on gene modified T-cells
22 Apr 2016
MMRF presents highlights for patients at Myeloma 2016
22 Apr 2016
Myeloma 2016: Panel discussion on novel treatments
06 Dec 2014
ASH 2014: Ask the experts Q&A session 1
Chronic Lymphocytic Leukemia (CLL)
27 May 2026
BTK inhibitors in CLL: sequencing, combinations, and advice for the community
11 May 2026
Fixed-duration versus continuous therapy in CLL: clinical considerations, the CLL17 trial, & more
25 Apr 2026
Updates on T-cell engagers and CARs in CLL: liso-cel, novel agents, and resistance mechanisms
28 Sep 2025
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
13 Jun 2025
Identifying and targeting survival co-dependencies of CLL resistant to venetoclax
11 Apr 2025
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
10 Apr 2025
Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy
20 Mar 2025
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
11 Oct 2024
Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders
10 Oct 2024
CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products
16 Jun 2024
Updates in CLL from EHA 2024: combinations of BTK and BCL2 inhibitors, BTK degraders, and more
16 Jun 2024
Updates in the treatment of CLL from EHA 2024
29 May 2024
An update on CAR-T in CLL
25 Mar 2024
MBL: biology, classification & the possibility of early interception
25 Mar 2024
Richter’s transformation: biology & ongoing trials in the field
14 Mar 2024
Roundtable Discussions from IBC 2024
24 Jun 2023
Latest advances in BTK inhibitors from EHA 2023
08 Jun 2023
Updates in BTK inhibitors from EHA 2023
12 May 2023
Updates in CLL
10 Dec 2022
Key highlights from ASH 2022
10 Dec 2022
Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis
14 Oct 2022
CLL updates from SOHO 2022: novel treatment strategies, the promise of next-generation BTK inhibitors & more
29 Sep 2022
Key highlights from SOHO 2022
30 Apr 2022
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
30 Apr 2022
Exploring the potential of CAR-T therapy in CLL
30 Apr 2022
CLL updates from iwCAR-T 2022
13 Dec 2021
Updates in CLL: key clinical trials in the frontline and R/R setting, pre-clinical data and MRD
11 Dec 2021
Exploring key ASH 2021 clinical trials in the frontline and R/R setting
26 Jul 2021
Post-EHA/ICML 2021
12 Jan 2021
Post-ASH 2020
03 Aug 2020
ASCO & EHA 2020
08 Nov 2019
Day 1 round up: CAR T-cell products
11 Oct 2019
Day 1 round up: CAR-T toxicity
11 Oct 2019
CLL and CAR-T
22 Sep 2019
Highlights from iwCLL 2019: MRD and novel therapies
22 Sep 2019
Predictors in the novel therapy era
21 Sep 2019
Varying efficacies of combination and monotherapies in CLL
21 Sep 2019
Assessing the role of CAR-T in CLL
20 Sep 2019
CLL biology and patient stratification
20 Sep 2019
MRD assessment and the treatment of patients in the 'real world'
14 Sep 2019
WM: BTK inhibitors
13 May 2017
How can doctors help empower CLL patients?
12 May 2017
Evolving CLL treatments: creating choices and igniting discussions
12 May 2017
2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
12 May 2017
Looking beyond the leukemic cell for answers
12 May 2017
Inherited and acquired genetic factors involved in the development of CLL
12 May 2017
Promising future leaders in CLL research
12 May 2017
Why should young investigators join the CLL community?
12 May 2017
Diagnosis and Initial Treatment of CLL
29 Feb 2016
iwCLL – International Workshop on Chronic Lymphocytic Leukemia
04 Dec 2015
Round table with Prof. John Gribben and Prof. Stephan Stilgenbauer on CLL
04 Dec 2015
Is the era of chemotherapy over in CLL?
04 Dec 2015
Combination treatment regimens for CLL
04 Dec 2015
The promise of second-generation PI3K inhibitors for CLL
04 Dec 2015
Can we afford to have CLL patients on a therapy for the rest of their lives?
04 Dec 2015
Overview of RESONATE-2 clinical trial of ibrutinib in CLL
04 Dec 2015
Importance of Bcl-2-targeted therapies
04 Dec 2015
Highlights of ASH in CLL
03 Dec 2015
Phase II trial of venetoclax monotherapy for relapsed/refractory CLL with 17p deletion
Acute Myeloid Leukemia (AML)
25 Apr 2026
Cellular therapy approaches in AML: novel targets, off-the-shelf CARs, & NK-cell therapy
19 Mar 2026
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
21 Oct 2025
The value and mission of the International Workshop on Acute Leukemias
20 Sep 2025
Immunotherapy in AML: translational insights and promising avenues being explored
19 Sep 2025
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
19 Sep 2025
Debate: the value and utility of MRD in the management of adults with newly-diagnosed AML
19 Sep 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
19 Sep 2025
Is pre-transplant intervention warranted in patients with MRD-positive AML?
19 Sep 2025
Menin inhibitors in AML: combinations, resistance, and future directions
13 Apr 2025
T-cell engagers and CARs in myeloid malignancies
18 Mar 2025
Menin inhibition in AML: clinical guidance and future directions
17 Mar 2025
Venetoclax resistance in AML: mechanisms and strategies to overcome
17 Mar 2025
Menin inhibition in AML: clinical guidance and future directions
17 Mar 2025
Venetoclax resistance in AML
17 Mar 2025
A study investigating long-term survivorship outcomes in AML
01 Oct 2024
Novel targets, combinations & treatments in AML: use of OGM, TP53 treatment strategies & ADCs
01 Oct 2024
Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease
24 Sep 2024
Current data on menin inhibition in AML
24 Sep 2024
Discussion: should less intensive therapy be used in all older newly diagnosed pts with AML, even if fit for intensive chemo?
20 Aug 2024
Prolonging remission in AML: current approaches & future outlooks
18 Jul 2024
Ongoing research in the NIH Myeloid Malignancies Program
17 Jul 2024
Updates in HR-MDS therapies: IDH inhibitors, challenges with transplantation, and more
17 Jul 2024
Response assessment & regulatory considerations in MDS
16 Jul 2024
Approaching TP53-mutated MDS and secondary AML
30 May 2024
The future of CAR-T therapy in AML
11 Dec 2023
Discovery of a new predisposition gene, ERG, for bone marrow failure and hematological malignancy
04 Sep 2023
Clonal hematopoiesis, early detection & potential therapeutics
04 Sep 2023
New treatments in AML: FLT3 inhibitors & novel combinations
04 Sep 2023
TP53 mutation in AML
04 Sep 2023
Novel targets, combinations & treatments
04 Sep 2023
Transplantation & immunotherapies
25 Aug 2023
iwAL 2023
01 Jun 2023
Updates in AML
16 Apr 2023
AML highlights from iwCAR-T 2023
12 Apr 2023
Improving transplant outcomes in AML
21 Mar 2023
Improving transplantation outcomes in AML
29 Sep 2022
Standard of care in AML in 2022
29 Sep 2022
Novel targets, treatments, and combinations in AML
29 Sep 2022
What do we know about drug resistance in AML?
29 Sep 2022
Immunotherapeutics in AML
29 Sep 2022
Current challenges in clinical genomics
16 Sep 2022
iwAL 2022
30 Apr 2022
Addressing the major challenges to CAR-T therapy in AML
30 Apr 2022
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
30 Apr 2022
AML updates from iwCAR-T 2022
11 Dec 2021
Updates in FLT3+ from ASH 2021
11 Dec 2021
Discussing FLT3-mutated AML: top ASH data, triplets, and exciting future strategies
06 Jul 2021
Post-EHA/ASCO 2021
30 Apr 2021
Prognostic relevance of monocytic switch and future research
14 Jan 2021
Post-ASH 2020
26 Nov 2020
FLT3-Mutated AML
03 Nov 2020
Venetoclax-Based Regimens
21 Oct 2020
IDH Inhibitors
07 Oct 2020
Immunotherapy
16 Jul 2020
EHA & ASCO 2020
11 Oct 2019
Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
18 Jun 2019
The future treatment of acute leukemias: part II
18 Jun 2019
The future treatment of acute leukemias: part I
28 May 2019
Novel approaches and targeted therapies in 2019 for AML
28 May 2019
iwAL 2019: CAR-T & cellular therapies in AML and ALL
17 May 2019
Utilizing MRD for AML in the clinical setting
17 May 2019
Immunotherapy for AML & ALL
17 May 2019
AML treatment: what does the data say?
17 May 2019
Biological mechanisms of AML: a 2019 update
02 Mar 2018
iwAL 2018 day 2 discussion: novel approaches and targeted therapies in AML
02 Mar 2018
Genomics and acute leukemia management: artificial intelligence, deep learning & pre-leukemic clones
02 Mar 2018
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
02 Mar 2018
Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy
17 Feb 2018
Acute leukemias: is MRD already a surrogate for survival?
17 Feb 2018
MRD for acute leukemias: opinion from both sides of the Atlantic
17 Feb 2018
Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy
17 Feb 2018
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
17 Feb 2018
Challenging the norms for elderly AML treatment: clinical trials & intensive therapy
06 Dec 2014
ASH 2014: Ask the experts Q&A session 2
Myelodysplastic Syndromes (MDS)
19 Mar 2026
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
18 Mar 2026
Myeloid Monthly: Updates from CAM
20 Sep 2025
Refining the diagnosis and classification of CMML
29 Jun 2025
iwMDS wrap-up: translating research into practice to optimize patient care
28 Jun 2025
Evolving strategies in clinical trial design for MDS: defining response criteria
28 Jun 2025
Novel targets in MDS: telomerase inhibition, the SELECT-MDS-1 trial, PK agonists, & more
28 Jun 2025
Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more
28 Jun 2025
Advances made in MDS classification and risk stratification: ongoing work & future perspectives
15 Oct 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
24 Sep 2024
Updates on established therapies in AML - Part 1
19 Jul 2024
Day 1 highlights: imetelstat in MF, challenges with MPN/MDS overlap syndromes & future outlooks
18 Jul 2024
Aiming to advance the diagnosis and treatment of CMML and BPDCN
18 Jul 2024
Ongoing research in the NIH Myeloid Malignancies Program
17 Jul 2024
Response assessment & regulatory considerations in MDS
17 Jul 2024
Updates in the diagnosis, classification & risk stratification of MDS
17 Jul 2024
Updates in LR-MDS treatment: imetelstat and luspatercept, standardizing PROs, and using AI to improve risk stratification
17 Jul 2024
Inflammation & immune interventions in MDS: targeting STAT, IRAK4 & more
17 Jul 2024
Updates in HR-MDS therapies: IDH inhibitors, challenges with transplantation, and more
16 Jul 2024
New directions and governmental progress in MDS: insights into MyeloMATCH & CTEP
16 Jul 2024
New trends in CHIP/CCUS: impact of CH on transplant outcomes & distinguishing between MDS & CCUS
16 Jul 2024
Approaching TP53-mutated MDS and secondary AML
01 Jul 2024
Novel developments in lower-risk MDS & important practical considerations when treating patients
14 Jun 2024
The i4MDS consortium and immune monitoring in MDS
13 Jun 2024
The i4MDS consortium and immune monitoring in MDS
30 May 2024
The future of CAR-T therapy in AML
13 May 2024
Treating lower-risk MDS beyond ESA failure
01 May 2024
Treating lower-risk MDS: practical management of anemia
28 Mar 2024
TP53 mutation in MDS
25 Mar 2024
CHIP: clinical relevance, challenges & preventing myeloid malignancies
25 Mar 2024
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
21 Mar 2024
Novel agents being explored in lower- and higher-risk MDS
14 Mar 2024
Roundtable discussions from IBC 2024
11 Dec 2023
Discovery of a new predisposition gene, ERG, for bone marrow failure and hematological malignancy
27 Oct 2023
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
07 Sep 2023
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
18 May 2023
Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS
05 May 2023
Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS
01 Mar 2023
Comparing the ICC and WHO classifications for MDS & their impact on clinical practice
12 Dec 2022
Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more
10 Dec 2022
Key highlights from ASH 2022
24 Jul 2022
Inflammation, immune dysregulation and targeting in MDS
24 Jun 2022
iwMDS 2022
24 Jun 2022
Updates in classification and risk stratification in MDS
24 Jun 2022
Clonal hematopoiesis and pre-MDS states
24 Jun 2022
How can we improve the efficiency of drug approval in MDS?
24 Jun 2022
Key highlights from iwMDS 2022
30 Apr 2022
Addressing the major challenges to CAR-T therapy in AML
11 Apr 2022
The impact of AI in MDS
11 Dec 2021
What did ASH 2021 mean for MDS?
11 Dec 2021
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies
05 Jul 2021
Post-EHA/ASCO 2021
11 May 2021
Women in Science
25 Feb 2021
Giants in MDS
25 Feb 2021
Diagnosis & Prognosis
04 Feb 2021
Global Perspectives
20 Jan 2021
Post-ASH 2020
03 Dec 2020
Lower-Risk Disease
12 Nov 2020
Latest Updates
Myeloproliferative Neoplasms (MPNs)
19 Mar 2026
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
28 Jun 2025
Challenges of managing blast-phase MPNs: the role of transplant, impact of TP53 mutations & more
27 Jun 2025
Challenging and uncommon scenarios in MPNs
27 Jun 2025
Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity
27 Jun 2025
Novel approaches to upfront management of myelofibrosis
13 Apr 2025
T-cell engagers and CARs in myeloid malignancies
07 Dec 2024
Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms
15 Oct 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
23 Aug 2024
The inaugural MPN Workshop of the Carolinas: the importance of the meeting for the MPN community
19 Jul 2024
Unmet needs in MF and focusing on early intervention in patients with MPNs
19 Jul 2024
Day 1 highlights: imetelstat in MF, challenges with MPN/MDS overlap syndromes & future outlooks
18 Jul 2024
Aiming to advance the diagnosis and treatment of CMML and BPDCN
17 Jul 2024
Updates in LR-MDS treatment: imetelstat and luspatercept, standardizing PROs, and using AI to improve risk stratification
16 Jul 2024
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
15 Jul 2024
Considering the use of symptom response as an endpoint in myelofibrosis clinical trials
11 Dec 2023
Key highlights from ASH 2023
11 Dec 2023
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
12 Dec 2022
Key highlights from ASH 2022
12 Dec 2022
Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy
22 Sep 2022
Key highlights from the 2022 Texas MPN Workshop
26 Aug 2022
Drivers of progression in MPNs and the importance of early intervention
26 Aug 2022
Key updates from the 2022 Texas MPN Workshop
12 Jun 2022
MPN Sessions: Key updates from EHA 2022
11 Jun 2022
Key updates from EHA 2022
12 Dec 2021
Key takeaways in MPNs
11 Dec 2021
Key updates from ASH 2021
15 Jul 2021
Post-EHA/ASCO 2021
15 Jan 2021
Post-ASH 2020
15 Sep 2020
2020 Texas MPN Workshop
Lymphoma
26 Apr 2026
Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
25 Apr 2026
An update on T-cell engagers in follicular lymphoma and large B-cell lymphoma
25 Apr 2026
Novel cellular therapy approaches in NHL: NK-cell therapies, allo and in vivo CARs, and more
20 Oct 2025
Advances in MCL treatment: insights from TRIANGLE, the changing role of SCT & novel targeted agents
02 Oct 2025
Advances in mantle cell lymphoma treatment - insights from TRIANGLE, BTKis, and the changing role of SCT
28 Sep 2025
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
28 Sep 2025
Expanding the CAR platform for NHL
28 Sep 2025
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
27 Sep 2025
Novel therapies and ongoing trials in NHL: advances in antibody-based combinations
27 Sep 2025
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
23 Sep 2025
Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists
13 Apr 2025
Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics
13 Apr 2025
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
12 Apr 2025
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
12 Apr 2025
CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations
28 Mar 2025
Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more
19 Mar 2025
Sequencing therapies in R/R DLBCL, MCL & FL
13 Mar 2025
The value of BTK inhibitors in the treatment of frontline and relapsed MCL: expert insights
07 Mar 2025
Evaluating the role of stem cell transplantation vs CAR-T therapy in LBCL
07 Mar 2025
Exploring the role of BTK inhibitors in frontline and R/R mantle-cell-lymphoma
07 Feb 2025
A European study investigating patient-reported outcomes of CAR T-cell therapy
11 Oct 2024
ADCs in B-cell lymphomas: emerging data and novel targets
11 Oct 2024
Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders
10 Oct 2024
Bispecific antibodies in NHL: comparisons with CAR-T, managing toxicities, & combination approaches
10 Oct 2024
CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products
09 Oct 2024
Evolving frontline treatment in MCL: disease biology, the changing role of SCT & novel agents
09 Oct 2024
Updates in T-cell leukemia/lymphoma
14 Jun 2024
The role of BTK inhibitors in the treatment of MCL: ongoing trials and future outlooks
14 Mar 2024
Roundtable discussions from IBC 2024
17 Oct 2023
Evolving treatment landscape of MCL
17 Oct 2023
Novel therapies in NHL: antibody-drug conjugates
17 Oct 2023
New therapeutic targets in DLBCL
17 Oct 2023
Updates on the biology and treatment of T-cell lymphoma
17 Oct 2023
Expanding the CAR platform in NHL
17 Oct 2023
Novel therapies in NHL: BTK inhibitors & degraders
17 Oct 2023
Bispecific antibodies in NHL
29 Sep 2023
iwNHL 2023
24 Jun 2023
Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023
09 Jun 2023
PDX mice as representative models for T-cell lymphoma
08 Jun 2023
Updates in CAR-T & bispecific antibodies from EHA 2023
12 May 2023
Lymphoma CAR and bispecific updates
12 Dec 2022
Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks
12 Dec 2022
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
10 Dec 2022
Key highlights in T-cell lymphoma from ASH 2022
10 Dec 2022
Key highlights in NHL from ASH 2022
10 Sep 2022
iwNHL 2022
18 Aug 2022
Key updates in lymphoma and impact on UK clinical practice
10 Jun 2022
Upcoming trials and agents in T-cell lymphoma
18 May 2022
Lymphoma Sessions: CAR-T and lymphoma treatment in the UK
01 May 2022
Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma
01 May 2022
Advances in CAR-T therapy for lymphoma
30 Apr 2022
Lymphoma updates from iwCAR-T 2022
04 Apr 2022
Updates from the lymphoma & CLL session: clinical trials, novel agents, and more
03 Apr 2022
CAR-T and lymphoma treatment in the UK
01 Feb 2022
Post-ASH 2021
15 Oct 2021
Highlighting unmet needs for CTCL
29 Jul 2021
Post-EHA/ICML 2021
19 Jan 2021
Post-ASH 2020 UK
19 Jan 2021
Post-ASH 2020
08 Nov 2019
Day 1 round up: CAR T-cell products
11 Oct 2019
Expert discussion on CAR-T updates in lymphoma
11 Oct 2019
Day 1 round up: CAR-T toxicity
17 Sep 2019
CAR-T vs bispecific antibodies for lymphoma
17 Sep 2019
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
17 Sep 2019
The need for academic and pharmaceutical collaboration in drug development
17 Sep 2019
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization
16 Sep 2019
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1
14 Sep 2019
Current frontline treatment for WM
14 Sep 2019
WM: BTK inhibitors
13 Sep 2019
CAR-T for lymphoma: new targets, real world data & resistance
13 Sep 2019
Targeted therapy in MM
06 Sep 2019
Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think?
01 Oct 2018
Pathobiology and clinical management of T-cell lymphoma
25 Sep 2018
Novel targets and agents for lymphoma
22 Sep 2018
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
21 Sep 2018
iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine
21 Sep 2018
CAR T-cells in lymphoma: where are we now?
21 Sep 2018
Immunotherapy for NHL: checkpoint inhibitors, considerations & the future
21 Sep 2018
Novel diagnostics & biomarkers for DLBCL and CTCL
21 Sep 2018
Cellular therapy and drug access for viral lymphomas
21 Sep 2018
Precision medicine in lymphoma
21 Sep 2018
Viral lymphomas: risk factors and treatments
17 Feb 2018
Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies
08 Sep 2017
How immunotherapies are re-shaping the treatment of lymphoma
08 Sep 2017
Describing clonal evolution in lymphoma
08 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
08 Sep 2017
Novel lymphoma targets and agents
24 Sep 2016
iwNHL 2016: Highlights from Day 1
23 Sep 2016
Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure
23 Sep 2016
Panel discussion on mantle cell lymphoma
09 Apr 2015
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Cellular Therapy Sessions
26 Apr 2026
T-cell engagers & CARs for myeloma: trispecifics, anito-cel updates, & long-term CARTITUDE-4 data
26 Apr 2026
Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
25 Apr 2026
Novel cellular therapy approaches in NHL: NK-cell therapies, allo and in vivo CARs, and more
25 Apr 2026
Updates on T-cell engagers and CARs in CLL: liso-cel, novel agents, and resistance mechanisms
25 Apr 2026
Cellular therapy approaches in AML: novel targets, off-the-shelf CARs, & NK-cell therapy
25 Apr 2026
The future of T-cell engagers and CARs in acute lymphoblastic leukemia
12 Apr 2026
Immunotherapies in myeloma: novel bispecific data, off-the-shelf CAR-T, and trispecific approaches
12 Apr 2026
Early use of immunotherapy in myeloma: TecDara, bispecific consolidation, and alpha emitter therapy
11 Apr 2026
Novel approaches to targeting resistance mechanisms in multiple myeloma
13 Mar 2026
Treatment considerations with GPRC5D-targeted therapies in myeloma: optimizing sequencing
12 Mar 2026
GPRC5D-directed therapies in myeloma: mechanisms of resistance & strategies to overcome resistance
12 Mar 2026
Latest real-world & clinical evidence with GPRC5D therapies: toxicity, safety & QoL
24 Oct 2025
Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting
24 Oct 2025
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
20 Oct 2025
Advances in MCL treatment: insights from TRIANGLE, the changing role of SCT & novel targeted agents
28 Sep 2025
Expanding the CAR platform for NHL
23 Sep 2025
Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists
20 Sep 2025
Immunotherapy in AML: translational insights and promising avenues being explored
19 Sep 2025
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
27 Jun 2025
Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity
13 Apr 2025
Important considerations for community oncologists regarding the use of T-cell therapies in myeloma
13 Apr 2025
T-cell engagers and CARs in myeloid malignancies
13 Apr 2025
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
13 Apr 2025
Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics
12 Apr 2025
CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations
12 Apr 2025
Improving access and delivery of CAR T-cells and bispecific antibodies in the community
12 Apr 2025
Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more
12 Apr 2025
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
12 Apr 2025
Integrating autoimmune diseases into cellular therapy centers
11 Apr 2025
CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more
11 Apr 2025
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
28 Mar 2025
Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more
07 Feb 2025
A European study investigating patient-reported outcomes of CAR T-cell therapy
08 Dec 2024
Amyloidosis Sessions: Highlights from ASH 2024
07 Dec 2024
Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms
04 Nov 2024
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
04 Nov 2024
CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs
04 Nov 2024
Defining high-risk multiple myeloma: recent advances in the field & future considerations
15 Oct 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
11 Oct 2024
ADCs in B-cell lymphomas: emerging data and novel targets
10 Oct 2024
Bispecific antibodies in NHL: comparisons with CAR-T, managing toxicities, & combination approaches
10 Oct 2024
CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products
09 Oct 2024
Updates in T-cell leukemia/lymphoma
09 Oct 2024
Evolving frontline treatment in MCL: disease biology, the changing role of SCT & novel agents
30 May 2024
CAR T-cells for autoimmune diseases
30 May 2024
The future of CAR-T therapy in AML
29 May 2024
An update on CAR-T in CLL
03 May 2024
The value of genomics in multiple myeloma & applying this in clinical practice
03 May 2024
Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more
03 May 2024
Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities
03 May 2024
History and upcoming projects of the MMRF
17 Oct 2023
New therapeutic targets in DLBCL
17 Oct 2023
Expanding the CAR platform in NHL
17 Oct 2023
Evolving treatment landscape of MCL
04 Sep 2023
Transplantation & immunotherapies
24 Jun 2023
Key myeloma highlights from EHA 2023
24 Jun 2023
Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023
01 Jun 2023
Updates in AML
12 May 2023
Rapid CAR manufacture
12 May 2023
Current challenges in CAR-T
12 May 2023
Updates in ALL
12 May 2023
Updates in CLL
12 May 2023
Updates in multiple myeloma
12 May 2023
Prophylaxis and management of CRS & ICANS
21 Apr 2023
Looking forward to the EBMT 2023 Trainee Day
16 Apr 2023
AML highlights from iwCAR-T 2023
15 Apr 2023
Resistance mechanisms mediated by the microenvironment in multiple myeloma
15 Apr 2023
The future of myeloma therapy
15 Apr 2023
Novel therapeutic strategies in multiple myeloma
15 Apr 2023
Reaching a cure for multiple myeloma
14 Mar 2023
iwCAR-T 2023
12 Dec 2022
Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks
12 Dec 2022
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
10 Dec 2022
Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks
29 Sep 2022
Immunotherapeutics in AML
29 Sep 2022
T-cell engagers and treating relapsed ALL
15 Sep 2022
Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
15 Sep 2022
The role of super-enhancers in multiple myeloma & mechanisms of resistance to IMiDs and T cell-directed therapies
15 Jul 2022
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
10 Jun 2022
Upcoming trials and agents in T-cell lymphoma
18 May 2022
Lymphoma Sessions: CAR-T and lymphoma treatment in the UK
30 Apr 2022
Patient-reported outcomes in CAR-T recipients
30 Apr 2022
Exploring the potential of CAR-T therapy in CLL
30 Apr 2022
Addressing the major challenges to CAR-T therapy in AML
30 Apr 2022
The future of CAR-T therapy in ALL
27 Mar 2022
Day 2 wrap-up: pushing myeloma boundaries
27 Mar 2022
T-Cell Engagers: targets, challenges and opportunity
26 Mar 2022
Novel targets in 2022
26 Mar 2022
Genomics in the age of I-O
11 Feb 2022
EBMT Trainee Committee & Young EHA Ambassadors: educating trainees about CAR-T
11 Dec 2021
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies
11 Sep 2021
Next steps for myeloma research and treatment
11 Sep 2021
Patient segmentation for targeted therapy in myeloma
10 Sep 2021
The new era of myeloma therapies
10 Sep 2021
Precursor conditions: management of smoldering myeloma
09 Sep 2021
Long-term disease-free survival in myeloma
08 Nov 2019
Day 1 round up: CAR T-cell products
11 Oct 2019
Expert discussion on CAR-T updates in lymphoma
11 Oct 2019
Toxicity issues with CAR T-cell therapy
11 Oct 2019
What's the latest on CAR-T in ALL?
11 Oct 2019
CLL and CAR-T
11 Oct 2019
CAR T-cell therapy in myeloma
11 Oct 2019
Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
11 Oct 2019
Day 1 round up: CAR-T toxicity
21 Sep 2019
Assessing the role of CAR-T in CLL
17 Sep 2019
CAR-T vs bispecific antibodies for lymphoma
14 Sep 2019
MRD evaluation: a key component of MM management?
13 Sep 2019
CAR-T for lymphoma: new targets, real world data & resistance
13 Sep 2019
CAR-T: hurdles and ladders
13 Sep 2019
Targeted therapy in MM
12 Sep 2019
Immunotherapy in myeloma: current strategies and future perspectives
18 Jun 2019
The future treatment of acute leukemias: part II
18 Jun 2019
The future treatment of acute leukemias: part I
28 May 2019
iwAL 2019: CAR-T & cellular therapies in AML and ALL
17 May 2019
Immunotherapy for AML & ALL
02 Dec 2018
The definitive guide to multiple myeloma at ASH 2018: part IV
22 Sep 2018
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
21 Sep 2018
CAR T-cells in lymphoma: where are we now?
09 Sep 2018
Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
07 Sep 2018
Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance
07 Sep 2018
CAR T-cells in myeloma: exploratory targets & payment models
07 Sep 2018
Where in the treatment sequence should CAR T-cells be used for myeloma?
17 Feb 2018
Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies
17 Feb 2018
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
18 Oct 2017
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
18 Oct 2017
The use of CAR T-cells in multiple myeloma
08 Sep 2017
How immunotherapies are re-shaping the treatment of lymphoma
23 Sep 2016
Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure
22 Apr 2016
Myeloma 2016: Panel discussion on gene modified T-cells
22 Apr 2016
Myeloma 2016: Panel discussion on novel treatments
Acute lymphoblastic leukemia (ALL)
25 Apr 2026
The future of T-cell engagers and CARs in acute lymphoblastic leukemia
11 Apr 2025
CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more
12 May 2023
Updates in ALL
29 Sep 2022
Novel treatment strategies in ALL
29 Sep 2022
ALL over the years
29 Sep 2022
T-cell engagers and treating relapsed ALL
29 Sep 2022
New frontiers in ALL - MRD for clinical practice
16 Sep 2022
iwAL 2022
30 Apr 2022
The future of CAR-T therapy in ALL
30 Apr 2022
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
30 Apr 2021
Myeloid switch of B-cell precursor ALL subtypes
30 Apr 2021
Prognostic relevance of monocytic switch and future research
08 Nov 2019
Day 1 round up: CAR T-cell products
11 Oct 2019
Day 1 round up: CAR-T toxicity
11 Oct 2019
What's the latest on CAR-T in ALL?
21 Sep 2019
Assessing the role of CAR-T in CLL
18 Jun 2019
The future treatment of acute leukemias: part II
18 Jun 2019
The future treatment of acute leukemias: part I
28 May 2019
iwAL 2019: CAR-T & cellular therapies in AML and ALL
17 May 2019
Immunotherapy for AML & ALL
17 May 2019
The evolving landscape of ALL therapy and the impact of MRD
17 May 2019
Biological mechanisms of AML: a 2019 update
02 Mar 2018
Genomics and acute leukemia management: artificial intelligence, deep learning & pre-leukemic clones
02 Mar 2018
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
17 Feb 2018
Acute leukemias: is MRD already a surrogate for survival?
17 Feb 2018
MRD for acute leukemias: opinion from both sides of the Atlantic
17 Feb 2018
Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies
17 Feb 2018
iwAL 2018: a plethora of new drugs & their impact on trial design
17 Feb 2018
iwAL 2018 day 1 discussion: treatment strategies in pediatric and adult ALL
17 Feb 2018
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
17 Feb 2018
Recent subtypes of ALL: Ph-like ALL and ETP ALL
17 Feb 2018
The evolving genomic landscape of ALL: molecular genetics, profiling and classification
06 Dec 2014
ASH 2014: Ask the experts Q&A session 2
06 Dec 2014
ASH 2014: Ask the experts Q&A session 1
Amyloidosis
08 Dec 2024
Highlights from ASH 2024
08 Dec 2024
Amyloidosis Sessions: Highlights from ASH 2024
11 Dec 2023
Highlights from ASH 2023
09 Dec 2023
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
23 Nov 2023
Updates in diagnosis, available therapies and the multidisciplinary team
07 Sep 2022
Highlights from ISA 2022
06 Sep 2022
The role of lysosomes in amyloidogenesis by mesangial cells
06 Sep 2022
Amyloidosis Sessions: Highlights from ISA 2022
06 Sep 2022
Amyloidosis Sessions: Highlights from ISA 2022
26 Mar 2022
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
26 Mar 2022
Novel targets in 2022
20 Jan 2021
Post-ASH 2020
14 Sep 2019
Amyloidosis: diagnosis and stem cell transplantation
14 Sep 2019
How will novel agents affect the amyloidosis population?
General Hematology
25 May 2026
Navigating life as an early-career physician: relocation, career transitions, burnout, & parenthood
26 Apr 2026
T-cell engagers & CARs for myeloma: trispecifics, anito-cel updates, & long-term CARTITUDE-4 data
26 Apr 2026
Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
25 Apr 2026
An update on T-cell engagers in follicular lymphoma and large B-cell lymphoma
25 Apr 2026
Novel cellular therapy approaches in NHL: NK-cell therapies, allo and in vivo CARs, and more
25 Apr 2026
Updates on T-cell engagers and CARs in CLL: liso-cel, novel agents, and resistance mechanisms
25 Apr 2026
Cellular therapy approaches in AML: novel targets, off-the-shelf CARs, & NK-cell therapy
25 Apr 2026
The future of T-cell engagers and CARs in acute lymphoblastic leukemia
12 Apr 2026
Immunotherapies in myeloma: novel bispecific data, off-the-shelf CAR-T, and trispecific approaches
12 Apr 2026
Early use of immunotherapy in myeloma: TecDara, bispecific consolidation, and alpha emitter therapy
11 Apr 2026
Integration of clinical and translational research in myeloma: ongoing work of the MMRF
11 Apr 2026
Advances in myeloma genomics: characterizing structural variation and identifying prognostic factors
11 Apr 2026
Novel approaches to targeting resistance mechanisms in multiple myeloma
11 Apr 2026
Expanding our understanding of the role of the tumor microenvironment in multiple myeloma
13 Mar 2026
Treatment considerations with GPRC5D-targeted therapies in myeloma: optimizing sequencing
12 Mar 2026
GPRC5D-directed therapies in myeloma: mechanisms of resistance & strategies to overcome resistance
12 Mar 2026
Latest real-world & clinical evidence with GPRC5D therapies: toxicity, safety & QoL
24 Oct 2025
Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting
24 Oct 2025
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
23 Oct 2025
Immuno- and targeted therapies in high-risk myeloma: ADCs, targeting GPRC5D & more
21 Oct 2025
The value and mission of the International Workshop on Acute Leukemias
20 Oct 2025
Advances in MCL treatment: insights from TRIANGLE, the changing role of SCT & novel targeted agents
28 Sep 2025
Expanding the CAR platform for NHL
28 Sep 2025
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
27 Sep 2025
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
27 Sep 2025
Novel therapies and ongoing trials in NHL: advances in antibody-based combinations
23 Sep 2025
Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists
20 Sep 2025
Immunotherapy in AML: translational insights and promising avenues being explored
19 Sep 2025
Is pre-transplant intervention warranted in patients with MRD-positive AML?
19 Sep 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
19 Sep 2025
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
29 Jun 2025
iwMDS wrap-up: translating research into practice to optimize patient care
27 Jun 2025
Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity
13 Apr 2025
Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics
13 Apr 2025
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
13 Apr 2025
Important considerations for community oncologists regarding the use of T-cell therapies in myeloma
13 Apr 2025
T-cell engagers and CARs in myeloid malignancies
12 Apr 2025
Integrating autoimmune diseases into cellular therapy centers
12 Apr 2025
Improving access and delivery of CAR T-cells and bispecific antibodies in the community
12 Apr 2025
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more
12 Apr 2025
Evaluating mechanisms of resistance to myeloma therapies & implications for clinical practice
12 Apr 2025
CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations
12 Apr 2025
Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more
12 Apr 2025
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
11 Apr 2025
Clinician & patient perspectives on the value of MRD in myeloma: what should patients know?
11 Apr 2025
Ongoing research at the MMRF: Horizon Clinical Trials Program
11 Apr 2025
CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more
11 Apr 2025
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
28 Mar 2025
Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more
13 Mar 2025
The value of BTK inhibitors in the treatment of frontline and relapsed MCL: expert insights
07 Feb 2025
A European study investigating patient-reported outcomes of CAR T-cell therapy
23 Jan 2025
Post-ASH 2024 Highlights
08 Dec 2024
Amyloidosis Sessions: Highlights from ASH 2024
07 Dec 2024
Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms
18 Nov 2024
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment & multidisciplinary care
04 Nov 2024
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
04 Nov 2024
CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs
04 Nov 2024
Defining high-risk multiple myeloma: recent advances in the field & future considerations
04 Nov 2024
An insight into designing randomized studies in high-risk myeloma
15 Oct 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
11 Oct 2024
ADCs in B-cell lymphomas: emerging data and novel targets
10 Oct 2024
Bispecific antibodies in NHL: comparisons with CAR-T, managing toxicities, & combination approaches
10 Oct 2024
CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products
09 Oct 2024
Updates in T-cell leukemia/lymphoma
09 Oct 2024
Evolving frontline treatment in MCL: disease biology, the changing role of SCT & novel agents
01 Oct 2024
Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease
01 Oct 2024
Novel targets, combinations & treatments in AML: use of OGM, TP53 treatment strategies & ADCs
26 Sep 2024
Analyzing the BM immune microenvironment in RAS/RAF-mutated myeloma treated with a MEK inhibitor
19 Jul 2024
Unmet needs in MF and focusing on early intervention in patients with MPNs
17 Jul 2024
Inflammation & immune interventions in MDS: targeting STAT, IRAK4 & more
16 Jul 2024
New directions and governmental progress in MDS: insights into MyeloMATCH & CTEP
14 Jun 2024
The role of BTK inhibitors in the treatment of MCL: ongoing trials and future outlooks
13 Jun 2024
The i4MDS consortium and immune monitoring in MDS
31 May 2024
BPDCN: treatment & management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
30 May 2024
CAR T-cells for autoimmune diseases
30 May 2024
The future of CAR-T therapy in AML
29 May 2024
An update on CAR-T in CLL
03 May 2024
The value of genomics in multiple myeloma & applying this in clinical practice
03 May 2024
Understanding mechanisms of resistance to targeted therapies in myeloma
03 May 2024
Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more
03 May 2024
Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities
03 May 2024
Novel targets & agents in myeloma
03 May 2024
History and upcoming projects of the MMRF
26 Mar 2024
The importance of cardio-oncology, awareness around the ESC 2022 guidelines & building a multidisciplinary team
25 Mar 2024
Early interception in SMM & novel agents being explored
12 Dec 2023
Key highlights in sickle cell disease at ASH 2023
12 Dec 2023
Key highlights in thalassemia at ASH 2023
11 Dec 2023
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
09 Dec 2023
Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored
17 Oct 2023
New therapeutic targets in DLBCL
17 Oct 2023
Expanding the CAR platform in NHL
17 Oct 2023
Bispecific antibodies in NHL
17 Oct 2023
Novel therapies in NHL: antibody-drug conjugates
17 Oct 2023
Evolving treatment landscape of MCL
27 Sep 2023
Session highlights and overview: exploring the cellular origins of multiple myeloma
15 Sep 2023
Should patients with AML receive treatment before transplantation?
04 Sep 2023
Transplantation & immunotherapies
24 Jun 2023
Key myeloma highlights from EHA 2023
24 Jun 2023
Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023
01 Jun 2023
Updates in AML
18 May 2023
Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS
12 May 2023
Rapid CAR manufacture
12 May 2023
Current challenges in CAR-T
12 May 2023
Prophylaxis and management of CRS & ICANS
12 May 2023
Lymphoma CAR and bispecific updates
12 May 2023
Updates in ALL
12 May 2023
Updates in CLL
12 May 2023
Updates in multiple myeloma
21 Apr 2023
Looking forward to the EBMT 2023 Trainee Day
15 Apr 2023
Resistance mechanisms mediated by the microenvironment in multiple myeloma
15 Apr 2023
Using animal models & the microenvironment to better understand the biology of multiple myeloma
15 Apr 2023
The future of myeloma therapy
15 Apr 2023
Novel therapeutic strategies in multiple myeloma
15 Apr 2023
Reaching a cure for multiple myeloma
12 Apr 2023
Improving transplant outcomes in AML
23 Feb 2023
Inhibition of RIP1 to prevent acute GvHD
12 Dec 2022
Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more
12 Dec 2022
Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks
12 Dec 2022
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
12 Dec 2022
Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy
11 Dec 2022
Identification of a T-cell population associated with outcomes in myeloma with t(4;14) translocation
10 Dec 2022
Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks
10 Dec 2022
Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis
14 Oct 2022
CLL updates from SOHO 2022: novel treatment strategies, the promise of next-generation BTK inhibitors & more
29 Sep 2022
Novel targets, treatments, and combinations in AML
29 Sep 2022
What do we know about drug resistance in AML?
29 Sep 2022
Immunotherapeutics in AML
29 Sep 2022
Novel treatment strategies in ALL
29 Sep 2022
ALL over the years
29 Sep 2022
T-cell engagers and treating relapsed ALL
29 Sep 2022
New frontiers in ALL - MRD for clinical practice
15 Sep 2022
Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
15 Sep 2022
Management of high-risk and frail patients, MRD & teclistamab
15 Sep 2022
The role of super-enhancers in multiple myeloma & mechanisms of resistance to IMiDs and T cell-directed therapies
06 Sep 2022
Amyloidosis Sessions: Highlights from ISA 2022
06 Sep 2022
Amyloidosis Sessions: Highlights from ISA 2022
24 Jul 2022
Inflammation, immune dysregulation and targeting in MDS
15 Jul 2022
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
14 Jun 2022
Myeloma treatment updates: a UK perspective
10 Jun 2022
Upcoming trials and agents in T-cell lymphoma
18 May 2022
Lymphoma Sessions: CAR-T and lymphoma treatment in the UK
03 May 2022
EBMT 2023 GvHD Highlights
30 Apr 2022
Patient-reported outcomes in CAR-T recipients
30 Apr 2022
Exploring the potential of CAR-T therapy in CLL
30 Apr 2022
Addressing the major challenges to CAR-T therapy in AML
30 Apr 2022
The future of CAR-T therapy in ALL
30 Apr 2022
Patient focused CAR-T updates
30 Apr 2022
iwCAR-T day 2 highlights
27 Mar 2022
Day 2 wrap-up: pushing myeloma boundaries
27 Mar 2022
T-Cell Engagers: targets, challenges and opportunity
26 Mar 2022
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
26 Mar 2022
Novel targets in 2022
26 Mar 2022
Genomics in the age of I-O
11 Feb 2022
EBMT Trainee Committee & Young EHA Ambassadors: educating trainees about CAR-T
11 Dec 2021
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies
11 Sep 2021
Next steps for myeloma research and treatment
11 Sep 2021
Patient segmentation for targeted therapy in myeloma
10 Sep 2021
The new era of myeloma therapies
10 Sep 2021
Precursor conditions: management of smoldering myeloma
09 Sep 2021
The IMW 2021 congress and COVID-19
09 Sep 2021
Long-term disease-free survival in myeloma
16 Apr 2021
Post-EBMT for Trainees
06 Apr 2021
Post-EBMT
23 Feb 2021
CAR-T & Nursing
22 Jan 2021
Post-ASH 2020
28 Jul 2020
COVID & Hematology
12 Jun 2020
Endotheliopathy is essential in COVID-19 associated coagulopathy
07 Dec 2019
The MAGIC algorithm probability: a novel response biomarker for acute GvHD
08 Nov 2019
Day 1 round up: CAR T-cell products
11 Oct 2019
Toxicity issues with CAR T-cell therapy
11 Oct 2019
Expert discussion on CAR-T updates in lymphoma
11 Oct 2019
What's the latest on CAR-T in ALL?
11 Oct 2019
CLL and CAR-T
11 Oct 2019
CAR T-cell therapy in myeloma
11 Oct 2019
Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
11 Oct 2019
Day 1 round up: CAR-T toxicity
25 Sep 2019
Highlights from IMW 2019 Part I
22 Sep 2019
Highlights from iwCLL 2019: MRD and novel therapies
21 Sep 2019
Assessing the role of CAR-T in CLL
20 Sep 2019
CLL biology and patient stratification
17 Sep 2019
CAR-T vs bispecific antibodies for lymphoma
17 Sep 2019
The need for academic and pharmaceutical collaboration in drug development
14 Sep 2019
Amyloidosis: diagnosis and stem cell transplantation
14 Sep 2019
How will novel agents affect the amyloidosis population?
14 Sep 2019
MRD evaluation: a key component of MM management?
13 Sep 2019
CAR-T: hurdles and ladders
12 Sep 2019
Immunotherapy in myeloma: current strategies and future perspectives
18 Jun 2019
The future treatment of acute leukemias: part II
18 Jun 2019
The future treatment of acute leukemias: part I
28 May 2019
Novel approaches and targeted therapies in 2019 for AML
28 May 2019
iwAL 2019: CAR-T & cellular therapies in AML and ALL
17 May 2019
Immunotherapy for AML & ALL
17 May 2019
AML treatment: what does the data say?
17 May 2019
The evolving landscape of ALL therapy and the impact of MRD
02 Dec 2018
The definitive guide to multiple myeloma at ASH 2018: part IV
22 Sep 2018
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
21 Sep 2018
CAR T-cells in lymphoma: where are we now?
21 Sep 2018
iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine
21 Sep 2018
Immunotherapy for NHL: checkpoint inhibitors, considerations & the future
21 Sep 2018
Cellular therapy and drug access for viral lymphomas
09 Sep 2018
Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
07 Sep 2018
Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance
07 Sep 2018
Myeloma 2018 day 1 highlights: precision medicine, epigenetics & novel targets
07 Sep 2018
CAR T-cells in myeloma: exploratory targets & payment models
07 Sep 2018
Where in the treatment sequence should CAR T-cells be used for myeloma?
20 Mar 2018
Global initiative: the EBMT Nurses Group collaborative project in India
17 Feb 2018
Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy
17 Feb 2018
Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies
17 Feb 2018
iwAL 2018: a plethora of new drugs & their impact on trial design
17 Feb 2018
iwAL 2018 day 1 discussion: treatment strategies in pediatric and adult ALL
17 Feb 2018
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
18 Oct 2017
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
18 Oct 2017
The use of CAR T-cells in multiple myeloma
18 Oct 2017
The future of immunotherapy in multiple myeloma
18 Oct 2017
Exciting new developments in multiple myeloma
08 Sep 2017
How immunotherapies are re-shaping the treatment of lymphoma
08 Sep 2017
Novel lymphoma targets and agents
22 Apr 2017
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
20 Feb 2017
Triple combination therapies for multiple myeloma (MM) patients
24 Sep 2016
iwNHL 2016: Highlights from Day 1
23 Sep 2016
Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure
23 Sep 2016
Panel discussion on T-cell lymphoma: current status of therapy and progress
16 Sep 2016
An update on immunotherapy for multiple myeloma in 2016
09 Jun 2016
EuroBloodNet European Reference Network - when will it be in place and why is collaboration crucial?
09 Jun 2016
An overview of the European Reference Networks and EuroBloodNet
09 Jun 2016
The role of patients and patient groups in the European Reference Network EuroBloodNet
05 May 2016
Myeloma 2016: Panel discussion on the new treatment paradigm
22 Apr 2016
Myeloma 2016: Panel discussion on gene modified T-cells
22 Apr 2016
MMRF presents highlights for patients at Myeloma 2016
22 Apr 2016
Myeloma 2016: Panel discussion on novel treatments
19 Feb 2016
